Sponsored by
Pharmaceutical Writers/Business Editors
MIAMI--(BUSINESS WIRE)--Nov. 19, 2004--IVAX Corporation
(AMEX:IVX)(LSE:IVX.L) announced today that positive phase II study
results were reported for Cervene(TM) (TP-38) to treat recurrent
glioblastoma, a highly malignant form of brain cancer.
In this study, patients with tumor progression after previous
surgery and radiation received an infusion of Cervene into their brain
cancer and surrounding brain tissue. Clear evidence of anti-tumor
activity was reported, with several patients achieving clinical
responses, including one patient with a complete response. The median
survival has not yet been reached, but is over 30 weeks which is
longer than expected. The investigators further reported that Cervene
was very well tolerated.
Dr. Phillip Frost, Chairman and CEO of IVAX commented, "The
positive results from this phase II trial and the favorable clinical
responses reported in an earlier phase I trial have encouraged IVAX to
initiate an expanded phase II trial involving 20 medical centers in
the United States and Europe. The progress made in the development of
Cervene is an example of IVAX' commitment to the development of novel
proprietary drugs for the treatment of serious illness."
IVAX Corporation, headquartered in Miami, Florida, discovers,
develops, manufactures, and markets branded and brand equivalent
(generic) pharmaceuticals and veterinary products in the U.S. and
internationally.
Copies of this and other news releases may be obtained free of
charge from IVAX' website at http://www.ivax.com.
This press release contains certain forward-looking statements
regarding product development efforts and product performance and
other non-historical facts, which are being are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. These statements involve risks and uncertainties that cannot
be predicted or quantified and, consequentially, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include,
among others, that phase II indications may not be indicative of
future results; that others may develop product formulations that are
superior to IVAX' formulations; and that phase II clinical trials for
Cervene(TM) (TP-38), and clinical trials for IVAX' other products
under development, may not be commenced or completed on a timely basis
or at all, may fail, may not achieve the expected results or
effectiveness and/or may not generate data that would support the
continued development, approval or marketing of these products for the
indications being studied or other indications. In addition to the
risk factors set forth above, IVAX' forward-looking statements may
also be adversely affected by general market factors, competitive
product development, product availability, federal and state
regulations and legislation, the regulatory process for new products
and indications, manufacturing issues that may arise, trade buying
patterns, patent positions and litigation, among other things. For
further details and discussion of these and other risks and
uncertainties, see IVAX' Annual Report on Form 10-K and other filings
with the Securities and Exchange Commission.
--30--JAR/mi*
CONTACT: IVAX Corporation, Miami
David Malina, 305-575-6043
Director/Investor Relations & Corporate Communications
KEYWORD: FLORIDA INTERNATIONAL CANADA
INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL PRODUCT
SOURCE: IVAX Corporation
Copyright Business Wire 2004
For the best viewing of the news releases please
use the following email settings: Courier 10 point.
- Notice of Copyright and General Disclaimer --
(c) 2004 Business Wire. All of the releases provided by Business Wire
are protected by copyright and other applicable laws, treaties and
conventions. Information contained in the releases is furnished by
Business Wire's members who are solely responsible for their content,
accuracy and originality. All reproduction, other than for an
individual user's reference, is prohibited without prior written
permission.